Adenoviral transduction of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity

Journal of Immunological Methods

Volumn 241, Issue 1-2, 2000, Pages 69-81

  Rouard, Hélène ^a   Léon, Anne ^b   Klonjkowski, Bernard ^c   Marquet, Jeanine ^a   Tennezé, Laurent ^d   Plonquet, Anne ^a   Agrawal, Samir G ^a   Abastado, Jean Pierre ^e   Eloit, Marc ^c   Farcet, Jean Pierre ^a   Delfau Larue, Marie Hélène ^a  

^a Service d'Immunologie Clinique   (France)

^b Etablissement Transfus Sang l'A   (France)

^c Ecl Veterinaire   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Immuno Designed Molecules   (France)

Author keywords

Human dendritic cell Anti tumor vaccination Adenoviral transduction

Indexed keywords

B7 ANTIGEN; BETA GALACTOSIDASE; CD1 ANTIGEN; CD14 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN GP 39; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 13; TUMOR ANTIGEN; TUMOR VACCINE; VIRUS VECTOR;

ADENOVIRUS; ADULT; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; LEUKAPHERESIS; MONOCYTE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TECHNIQUE;

ADENOVIRIDAE; ANTIGEN PRESENTATION; ANTIGENS, CD; BETA-GALACTOSIDASE; CANCER VACCINES; CELL DIFFERENTIATION; CELL SEPARATION; CELLS, CULTURED; CULTURE TECHNIQUES; DENDRITIC CELLS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULINS; LEUKAPHERESIS; LYMPHOCYTE CULTURE TEST, MIXED; MEMBRANE GLYCOPROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TRANSGENES;

ADENOVIRIDAE;

EID: 0343022266     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00214-3     Document Type: Article

References (34)

1. Arthur J.F., Butterfield L.H., Roth M.D., Bui L.A., Kiertscher S.M., Lau R., Dubinett S., Glaspy J., McBride W.H., Economou J.S. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4:1997;17.
2. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245.
3. Boyer A., Andreu G., Romet-Lemonne J.L., Fridman W.H., Teillaud J.L. Generation of phagocytic MAK and MAC-DC for therapeutic use: characterization and in vitro functional properties [In Process Citation]. Exp. Hematol. 27:1999;751.
4. Butterfield L.H., Jilani S.M., Chakraborty N.G., Bui L.A., Ribas A., Dissette V.B., Lau R., Gamradt S.C., Glaspy J.A., McBride W.H., Mukherji B., Economou J.S. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol. 161:1998;5607.
5. Diao J., Smythe J.A., Smyth C., Rowe P.B., Alexander I.E. Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther. 6:1999;845.
6. Diebold S.S., Lehrmann H., Kursa M., Wagner E., Cotten M., Zenke M. Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum. Gene Ther. 10:1999;775.
7. Dietz A.B., Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood. 91:1998;392.
8. Eloit M., Gilardi-Hebenstreit P., Toma B., Perricaudet M. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J. Gen. Virol. 71:1990;2425.
9. Fayette J., Dubois B., Vandenabeele S., Bridon J.M., Vanbervliet B., Durand I., Banchereau J., Caux C., Briere F. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J. Exp. Med. 185:1997;1909.
10. Gong J., Chen L., Chen D., Kashiwaba M., Manome Y., Tanaka T., Kufe D. Induction of antigen-specific antitumor immunity with adenovirus- transduced dendritic cells. Gene Ther. 4:1997;1023.
11. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:1997;3245.
12. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat. Med. 2:1996;52.
13. Kelleher P., Knight S.C. IL-12 increases CD80 expression and the stimulatory capacity of bone marrow-derived dendritic cells. Int. Immunol. 10:1998;749.
14. Kowalkowski K.L., Alzona M.T., Aono F.M., Van Epps D.E., Vachula M. Ex vivo generation of dendritic cells from CD34+ cells in gas-permeable containers under serum-free conditions. J. Hematother. 7:1998;403.
15. Lopez M., Amorim L., Gane P., Cristoph A., Bardinet D., Abina A.M., Minty A., Bernard J. IL-13 induces CD34+ cells isolated from G-CSF mobilized blood to differentiate in vitro into potent antigen presenting cells. J. Immunol. Methods. 208:1997;117.
16. Luft T., Pang K.C., Thomas E., Bradley C.J., Savoia H., Trapani J., Cebon J. A serum-free culture model for studying the differentiation of human dendritic cells from adult CD34+ progenitor cells. Exp. Hematol. 26:1998;489.
17. Morse M.A., Zhou L.J., Tedder T.F., Lyerly H.K., Smith C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. Ann. Surg. 226:1997;6.
18. Murphy G., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 29:1996;371.
19. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328.
20. Pardoll D.M. Cancer vaccines. Nat. Med. 4:1998;525.
21. Pickl W.F., Majdic O., Kohl P., Stockl J., Riedl E., Scheinecker C., Bello-Fernandez C., Knapp W. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J. Immunol. 157:1996;3850.
22. Piemonti L., Bernasconi S., Luini W., Trobonjaca Z., Minty A., Allavena P., Mantovani A. IL-13 supports differentiation of dendritic cells from circulating precursors in concert with GM-CSF. Eur. Cytokine Netw. 6:1995;245.
23. Reichardt V.L., Okada C.Y., Liso A., Benike C.J., Stockerl-Goldstein K.E., Engleman E.G., Blume K.G., Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood. 93:1999;2411.
24. Ribas A., Butterfield L.H., McBride W.H., Jilani S.M., Bui L.A., Vollmer C.M., Lau R., Dissette V.B., Hu B., Chen A.Y., Glaspy J.A., Economou J.S. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 57:1997;2865.
25. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T- helper and a T-killer cell. Nature. 393:1998;474.
26. Romani N., Reider D., Heuer M., Ebner S., Kampgen E., Eibl B., Niederwieser D., Schuler G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods. 196:1996;137.
27. Rosenfeld M.A., Siegfried W., Yoshimura K., Yoneyama K., Fukayama M., Stier L.E., Paakko P.K., Gilardi P., Stratford-Perricaudet L.D., Perricaudet M. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science. 252:1991;431.
28. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1997;1183.
29. Song W., Kong H.L., Carpenter H., Torii H., Granstein R., Rafii S., Moore M.A., Crystal R.G. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1997;1247.
30. Thurner B., Roder C., Dieckmann D., Heuer M., Kruse M., Glaser A., Keikavoussi P., Kampgen E., Bender A., Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods. 223:1999;1.
31. van Es W.L., Bont W.S. An improved method for the fractionation of human blood cells by centrifugal elutriation. Anal. Biochem. 103:1980;295.
32. Wan Y., Bramson J., Carter R., Graham F., Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8:1997;1355.
33. Zhong L., Granelli-Piperno A., Choi Y., Steinman R.M. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29:1999;964.
34. Zhou L.J., Tedder T.F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154:1995;3821.